Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Headache Pain ; 18(1): 21, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28197843

ABSTRACT

BACKGROUND: In the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting. METHODS: Patients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months. Two board-certified neurologist blinded to copeptin levels verified the endpoints after a structured 3-month-telephone interview. RESULTS: Of the 391 patients included, 75 (19%) had a serious secondary headache. Copeptin was associated with serious secondary headache (OR 2.03, 95%CI 1.52-2.70, p < 0.0001). Area under the curve (AUC) for copeptin to identify the primary endpoint was 0.70 (0.63-0.76). After adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms, copeptin remained an independent predictive factor for serious secondary headache (OR 1.74, 95%CI 1.26-2.39, p = 0.001). Moreover, copeptin improved the AUC of the multivariate logistic clinical model (p-LR-test < 0.001). Even though copeptin values were higher in patients reaching the secondary endpoint, this association was not significant in multivariate logistic regression. CONCLUSIONS: Copeptin was independently associated with serious secondary headache as compared to benign headaches forms. Copeptin may be a promising novel blood biomarker that should be further validated to rule out serious secondary headache in the emergency department. TRIAL REGISTRATION: Study Registration on 08/02/2010 as NCT01174901 at clinicaltrials.gov.


Subject(s)
Emergency Service, Hospital , Glycopeptides/blood , Headache/blood , Headache/diagnosis , Acute Disease , Aged , Area Under Curve , Biomarkers/blood , Female , Follow-Up Studies , Headache/physiopathology , Humans , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Assessment
2.
GMS Z Med Ausbild ; 29(2): Doc17, 2012.
Article in English | MEDLINE | ID: mdl-22558023

ABSTRACT

Increasing the flexibility of medical degree courses as well as individual advice and curriculum planning are essential needs of pregnant students and student parents. The results of the Ulm Study gave the academic advisers in the Dean of Studies' office in Heidelberg a large number of suggestions on how to offer sensitive, competent and needs-based advice to this target group. Comprehensive reflection on many years of experience in giving advice and recent survey results leads to a series of concrete measures which will contribute to more family-friendliness in Heidelberg's medical school.


Subject(s)
Child Rearing , Education, Medical , Faculty, Medical , Physicians, Women/psychology , Absenteeism , Career Choice , Child , Curriculum , Female , Germany , Humans , Male , Pregnancy , Social Support , Vocational Guidance , Work Schedule Tolerance
SELECTION OF CITATIONS
SEARCH DETAIL
...